Cytokinetics, IncorporatedCYTKNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank82
Year-over-Year Change
Year-over-year revenue growth rate
Percentile
P82
Within normal range
vs 2Y Ago
2.4x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 817.10% |
| Q3 2025 | -97.10% |
| Q2 2025 | 4128.56% |
| Q1 2025 | -90.67% |
| Q4 2024 | 3555.94% |
| Q3 2024 | 85.94% |
| Q2 2024 | -70.18% |
| Q1 2024 | -50.06% |
| Q4 2023 | 342.33% |
| Q3 2023 | -56.40% |
| Q2 2023 | -81.21% |
| Q1 2023 | 135.72% |
| Q4 2022 | -22.19% |
| Q3 2022 | -97.17% |
| Q2 2022 | 7649.83% |
| Q1 2022 | -97.94% |
| Q4 2021 | 922.62% |
| Q3 2021 | 91.24% |
| Q2 2021 | -56.58% |
| Q1 2021 | -2.59% |
| Q4 2020 | -83.88% |
| Q3 2020 | 1060.26% |
| Q2 2020 | -6.07% |
| Q1 2020 | -26.61% |
| Q4 2019 | -13.92% |
| Q3 2019 | -15.16% |
| Q2 2019 | -15.68% |
| Q1 2019 | -9.74% |
| Q4 2018 | -11.88% |
| Q3 2018 | 71.21% |
| Q2 2018 | 17.98% |
| Q1 2018 | 29366.67% |
| Q4 2017 | -100.29% |
| Q3 2017 | 102.42% |
| Q2 2017 | -26.49% |
| Q1 2017 | -87.47% |
| Q4 2016 | -43.88% |
| Q3 2016 | 917.70% |
| Q2 2016 | -31.10% |
| Q1 2016 | -13.69% |